211108-52-0

Basic information

• Product Name: TERT-BUTYL 3,4-TRANS-4-(BENZYLAMINO)-3-FLUOROPIPERIDINE-1-CARBOXYLATE RACEMATE
• Synonyms: TERT-BUTYL 3,4-TRANS-4-(BENZYLAMINO)-3-FLUOROPIPERIDINE-1-CARBOXYLATE RACEMATE;trans-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate;Tert butyl 3,4-Trans-4-(Benzylamino)-3-fluoropiperidine-1-carboxylate;Rel-(3R,4R)-4-Benzylamino-1-[tert-butoxycarbonyl]-3-fluoropiperidine
• CAS NO: 211108-52-0
• Molecular Formula: C17H25FN2O2
• Molecular Weight: 308.4
• Mol File: 211108-52-0.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 405.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• PKA: 7.98±0.40(Predicted)
• CAS DataBase Reference: TERT-BUTYL 3,4-TRANS-4-(BENZYLAMINO)-3-FLUOROPIPERIDINE-1-CARBOXYLATE RACEMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3,4-TRANS-4-(BENZYLAMINO)-3-FLUOROPIPERIDINE-1-CARBOXYLATE RACEMATE(211108-52-0)
• EPA Substance Registry System: TERT-BUTYL 3,4-TRANS-4-(BENZYLAMINO)-3-FLUOROPIPERIDINE-1-CARBOXYLATE RACEMATE(211108-52-0)

Safety Data

• Hazardous Substances Data: 211108-52-0(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL 3,4-TRANS-4-(BENZYLAMINO)-3-FLUOROPIPERIDINE-1-CARBOXYLATE RACEMATE is a chemical compound that is used as a racemic mixture in medicinal research and drug development. It is a piperidine derivative containing a tert-butyl ester group and a benzylamino group, as well as a fluorine atom. The compound is being investigated for its potential pharmacological properties, such as its ability to interact with biological targets and its potential as a therapeutic agent. Due to its structural complexity, TERT-BUTYL 3,4-TRANS-4-(BENZYLAMINO)-3-FLUOROPIPERIDINE-1-CARBOXYLATE RACEMATE is of interest to researchers in the pharmaceutical and medicinal chemistry fields.

Upstream product

• 100-46-9 benzylamine 
• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 211108-52-0 cis-4-benzylamino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester 
• 211108-52-0 (±)-cis-4-benzylamino-3-fluoropiperidine-1-carboxylic acid tert-butyl ester 
• 1208864-35-0 tert-butyl 3-fluoro-4,4-dihydroxypiperidin-1-carboxylic acid 
• 373604-28-5 3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 1070896-84-2 tert-butyl 3-fluoro-4-((methylsulfonyl)oxy)piperidine-1-carboxylate 
• 934536-10-4 (trans)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 100-52-7 benzaldehyde 
• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 

Downstream Products

• 211108-52-0 (3R,4R)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3S,4S)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 1260612-08-5 (3R,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 577691-56-6 (3S,4S)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 

Relevant articles and documents

Pyrrolamide DNA gyrase inhibitors: Optimization of antibacterial activity and efficacy

The pyrrolamides are a new class of antibacterial agents targeting DNA gyrase, an essential enzyme across bacterial species and inhibition results in the disruption of DNA synthesis and subsequently, cell death. The optimization of biochemical activity an

PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES

Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these